STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

May 31, 2004

Conditions
Melanoma
Interventions
DRUG

STA-4783

DRUG

Paclitaxel

Trial Locations (28)

23230

Virginia Cancer Institute, Richmond

23707

Office of James Stark, MD, Portsmouth

28207

Piedmont Oncology Specialists, Charlotte

40202

James Graham Brown Cancer Center - University Of Louisville, Louisville

46202

Indiana Oncology Hematology Consultants, Iindianapolis

47403

Cancer Care Center Of Southern Indiana, Bloomington

55422

Hubert H. Humphrey Cancer Center, Robbinsdale

58501

Odyssey Research and St. Alexius Medical Center, Bismarck

60068

Oncology Specialists, Park Ridge

60435

Joliet Oncology-Hematology Associates, Ltd., Joliet

63131

Mountainside Hospital, Suburban Surgical Associates, St Louis

65203

Ellis Fischels Cancer Center - Univ Of Missouri, Columbia

71913

Genesis Cancer Center, Hot Springs

80010

Anschutz Cancer Pavillion - Univ Of Colorado, Aurora

90404

Cancer Institute Medical Group, Inc, Santa Monica

92121

Scripps Cancer Center, San Diego

94109

Northern California Melanoma Center, San Francisco

96813

Research Institute Hawaii Pacific Health, Honolulu

72205-7101

Univ Of Arkansas/Arkansas Research Center, Little Rock

06902-3628

Hematology Oncology P.C., Stamford

06708

Medical Oncology and Hematology, P.C., Waterbury

30322-1013

Emory University - Winship Cancer Institute, Atlanta

46527-0139

Center For Cancer Care At Goshen Health, Goshen

47150-6809

Cancer Care Center, New Albany

04074

Maine Center for Cancer Medicine & Blood Disorders, Scarborough

97213-2933

Providence Cancer Center, Portland

24541-4155

Danville Hematology & Oncology, Inc., Danville

53792-0001

University of Wisconsin Medical School, Madison

All Listed Sponsors
lead

Synta Pharmaceuticals Corp.

INDUSTRY

NCT00084214 - STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma | Biotech Hunter | Biotech Hunter